Insulet Corporation Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Insulet Corporation's estimated annual revenue is currently $322M per year.
- Insulet Corporation received $340.2M in venture funding in November 2017.
- Insulet Corporation's estimated revenue per employee is $251,000
- Insulet Corporation has 1283 Employees.
- Insulet Corporation grew their employee count by 20% last year.
- Insulet Corporation currently has 94 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Insulet Corporation?
About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet's Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.keywords:Biotechnology,Healthcare,Medical Devices
Number of Employees
Employee Growth %
Insulet Corporation News
Shares of Insulet Corporation (PODD) (The Insulin Provider) for example have been on a relentless rally since they bottomed in 2009.
The Insulet Corporation offer is $800 million principal amount of 0.375% convertible senior notes due 2026, including $100 million principal ...
Insulet Corporation (PODD):. If you are considering getting into the day trading or penny stock market, it's a legitimate and profitable method for ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Insulet Corporation Funding
|2002-10-07||$22.0M||Spending On: Undiscl||Article|
|2006-02-17||$50.0M||Undisclosed||The Federated Kaufman Fund||Article|
|2009-03-17||$60.0M||Undisclosed||Deerfield Management Company||Article|
Insulet Corporation Executive Hires
|2004-07-21||Jeff Smith||VP Sales and Marketing||Article|
|2004-09-14||Shawna Gvazdauskas||VP Sales||Article|
|2006-03-24||Ruthann DePietro||VP Quality/Reg Aff||Article|
|2007-02-16||Luis Malave||Chief Operating Officer||Article|
|2008-09-04||Bill Arthur||VP Business Development||Article|
|2009-08-18||Peter Devlin||Chief Commercial Officer||Article|
|2013-01-24||Tracey H. Wielinski||VP Global Regulatory/Clinical Affairs/||Article|
|2014-09-17||Patrick J. Sullivan||President/CEO/Director||Article|
|2016-03-17||Aiman Abdel-Malek||SVP/Advanced Technology Engineering||Article|
|2016-09-07||Trang Ly||VP/Medical Director||Article|
|2017-05-31||Bret Christensen||Chief Commercial Officer||Article|
Insulet Corporation New Location/Offices